|Bid||117.54 x 900|
|Ask||126.10 x 800|
|Day's Range||120.53 - 125.00|
|52 Week Range||86.88 - 154.24|
|Beta (5Y Monthly)||1.24|
|PE Ratio (TTM)||24.57|
|Earnings Date||Aug 04, 2020 - Aug 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||153.76|
In this article we will take a look at whether hedge funds think Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips […]
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentations at the following virtual investor conferences:
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it and its partners will present seven new abstracts at the virtual American Society of Clinical Oncology (ASCO) Annual Meeting from May 29-June 2, 2020 and six abstracts at the virtual 25th Annual Congress of the European Hematology Association (EHA) from June 11-14, 2020. These new data from Jazz's expanding hematology and oncology portfolio and pipeline are focused on difficult-to-treat cancers, or related disorders, which have few, if any, treatment options.
It might not feel like it right now, as the coronavirus panic is roiling the stock market. But we're still technically in the longest bull market in history at 132 months and counting - a run that sent the best stocks of the group up by several thousand percent.That might not be the case for much longer, but nothing lasts forever. This bull market is destined to come to an end, like all the rest. But it's still worthwhile to stop and consider a run for stocks that shattered all longevity records.The great 1990s bull market (the previous title holder) lasted 113 months and saw the S&P; 500 advance by 417%. That market occurred during the dot-com era, of course, dominated by new technology stocks. The current bull market - which has seen the S&P; 500 advance by 339% - hasn't been quite as spectacular. But technology has been a big story here as well. Retail, medical devices and fintech also have a healthy representation among the biggest winners.Interestingly, energy stocks, which are under intense pressure right now, were underperformers in both epic bull runs.Today, on the 11th anniversary of the bull market, we're going to take a look at the 11 best stocks over that stretch, as well as the 11 biggest losers. To allow for a bigger pool of stocks, we expanded the universe to the full Russell 1000 Index - the 1,000 largest companies in America's equity market. SEE ALSO: 11 Defensive Dividend Stocks for Riding Out the Storm
Bionical Emas and Jazz Pharmaceuticals (NASDAQ: JAZZ) have entered into an agreement to provide appropriate patients in the United States (U.S.) who have relapsed Small Cell Lung Cancer (SCLC) lurbinectedin via an Expanded Access Program (EAP). Lurbinectedin is an investigational drug under review by the U.S. Food and Drug Administration (FDA).
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of Kim Sablich as executive vice president, general manager of North America, effective June 1, 2020. In this role, Ms. Sablich will lead Jazz's newly formed North American regional business structure, including Canada and the U.S., which brings together Medical Affairs, Commercial and Market Access teams for North America to create a strategically-aligned and integrated customer-facing organization. Ms. Sablich will report to Daniel Swisher, president and chief operating officer.
Jazz Pharmaceuticals (JAZZ) reports lower-than-expected first-quarter 2020 earnings and revenues. It lowers its guidance for 2020. Shares drop.
Jazz Pharmaceuticals (NASDAQ: JAZZ) ended 2019 on a positive note, with shares up 20%. Jazz stock is down more than 30%, wiping out all of the 2019 gains and then some. Here's why Jazz sang off-key in Q1.
Jazz (JAZZ) delivered earnings and revenue surprises of -31.82% and -0.68%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Jazz Pharmaceuticals (JAZZ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
It's time to shop for healthcare stocks that have suffered so far this year but should rebound in the long term thanks to growth drivers waiting in the wings. The first of these great deals, a pharmaceutical company, has a blockbuster on the market, a newer drug with growing sales, and possible drug approvals in the coming months. Jazz Pharmaceuticals (NASDAQ: JAZZ), a maker of sleep therapeutics and oncology drugs, has steadily grown annual revenue for more than a decade, announcing record annual revenue for 2019.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that enrollment in the Phase 3 clinical study of defibrotide for the prevention of hepatic veno-occlusive disease (VOD) post-hematopoietic stem-cell transplantation (HSCT) in high-risk or very high-risk patients is being discontinued. Enrollment in the study was stopped early based on the recommendation from an Independent Data Monitoring Committee (IDMC), which concluded it would be highly unlikely to reach statistical significance for the primary endpoint of VOD-free survival at Day +30 post-HSCT in the final analysis if the study were to complete enrollment.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2020 first quarter financial results on Tuesday, May 5, 2020, after the close of the financial markets. Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EDT/9:30 p.m. IST to discuss first quarter 2020 financial results and provide a business and financial update.
Ideally, your overall portfolio should beat the market average. But every investor is virtually certain to have both...
The company's rheumatoid arthritis drug blocks an effect of the immune system gone wild — a "storm" that turns COVID-19 deadly.
Drug developers are considered essential business, but the coronavirus has split staffs between home offices and labs.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today provided an update regarding the impact of COVID-19 on its business and the actions it is taking to mitigate the spread of this virus.
The biotechnology industry is comprised of hundreds of companies that fuse biology and technology to develop drugs and related products for the treatment of diseases and medical conditions. Today's biotechnology industry includes companies that make medical devices and diagnostics, as well as biofuels, biomaterials, pollution controls, and more.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) accepted for filing with Priority Review the company's New Drug Application (NDA) seeking marketing approval for JZP-258, an investigational medicine for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. JZP-258 is a novel oxybate product candidate with a unique composition of cations resulting in 92%, or approximately 1,000 to 1,500 milligrams, less sodium than Xyrem® (sodium oxybate). Xyrem is the only available product approved to treat both cataplexy and EDS in patients with narcolepsy ages 7 years and older and is the standard of care for treatment of cataplexy. The Prescription Drug User Fee Act (PDUFA) goal date for an FDA decision is July 21, 2020.